Shionogi & Co., Ltd. (OTCMKTS:SGIOF – Get Free Report) is anticipated to issue its results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $0.2771 per share and revenue of $1.12 billion for the quarter.
Shionogi & Co., Ltd. Stock Performance
SGIOF opened at $18.00 on Wednesday. Shionogi & Co., Ltd. has a twelve month low of $15.21 and a twelve month high of $26.00. The company’s 50-day moving average price is $17.82 and its two-hundred day moving average price is $19.02.
About Shionogi & Co., Ltd.
Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a focus on addressing infectious diseases and other significant unmet medical needs.
Its portfolio and development programs have included treatments for infectious diseases, central nervous system conditions, pain and other therapeutic areas. Shionogi is known for products such as Xofluza (baloxavir marboxil), an influenza treatment, and Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat bacterial infections.
Read More
- Five stocks we like better than Shionogi & Co., Ltd.
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Shionogi & Co. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
